Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study
| Autor: | Soon Ho Um, Soo-Young Park, Do Young Kim, Hye Jung Shin, Han Ah Lee, Yu Rim Lee, Beom Kyung Kim, Kwang Hyub Han, Eun Ju Lee, Hye Won Lee, Yeon Seok Seo, Young Oh Kweon, Jun Young Park, Seung Up Kim, Mi Na Kim, Won Young Tak, Sang Hoon Ahn |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male 0301 basic medicine Hepatitis B virus medicine.medical_specialty Carcinoma Hepatocellular Guanine Time Factors Genotype Epidemiology Rate ratio Antiviral Agents Gastroenterology 03 medical and health sciences Hepatitis B Chronic 0302 clinical medicine Risk Factors Internal medicine Republic of Korea Carcinoma medicine Humans Tenofovir business.industry Incidence Incidence (epidemiology) Liver Neoplasms Entecavir Middle Aged Hepatitis B medicine.disease digestive system diseases Confidence interval Molecular Typing 030104 developmental biology Liver Oncology 030220 oncology & carcinogenesis Hepatocellular carcinoma DNA Viral Population study Drug Therapy Combination Female Risk Adjustment business Follow-Up Studies medicine.drug |
| Zdroj: | Cancer Epidemiology, Biomarkers & Prevention. 29:832-837 |
| ISSN: | 1538-7755 1055-9965 |
| Popis: | Background: Long-term antiviral therapy (AVT) for chronic hepatitis B (CHB) reduces the risk of hepatocellular carcinoma (HCC). We assessed the temporal trends in the incidence of HCC over time during long-term AVT among Asian patients with CHB. Methods: Patients with CHB receiving entecavir/tenofovir (ETV/TDF) as a first-line antiviral were recruited from four academic hospitals in the Republic of Korea. We compared the incidence of HCC during and after the first 5 years of ETV/TDF treatment. Results: Among 3,156 patients, the median age was 49.6 years and males predominated (62.4%). During the follow-up, 9.0% developed HCC. The annual incidence of HCC per 100 person-years during the first 5 years (n = 1,671) and after the first 5 years (n = 1,485) was statistically similar (1.93% vs. 2.27%, P = 0.347). When the study population was stratified according to HCC prediction model, that is, modified PAGE-B score, the annual incidence of HCC was 0.11% versus 0.39% in the low-risk group ( 0.05). A Poisson regression analysis indicated that the duration of AVT did not significantly affect the overall trend of the incidence of HCC (adjusted annual incidence rate ratio = 0.85; 95% confidence interval, 0.66–1.11; P = 0.232). Conclusions: Despite long-term AVT, the risk of HCC steadily persists over time among patients with CHB in the Republic of Korea, in whom HBV genotype C2 predominates. Impact: Careful HCC surveillance is still essential. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|